Join Optimum Strategic Communications on Thursday, 6th October 2022 for our Annual Investor Healthcare Conference.
Now in its 14th year, the conference is now firmly established as a major thought leadership event in Europe, bringing together the top executives and visionaries from the healthcare industry and investment community to discuss and debate the trends set to reshape the industry far into the future.
We are thrilled to be returning to an in-person event this year, taking place at the Wellcome Collection, London.
Reviews from our past speakers on what makes Optimum's Healthcare Investor Conference unique.
Leading speakers from the healthcare and investment communities providing insights on the latest trends and impacts on the industry.
A selection of some of our brilliant panellists from previous years.
Dan Mahony Polar Capital
Kieran Murphy GE Healthcare
Mary Clark Optimum Strategic Communications
Oliver Maier Bayer.JPG)
Clive Cookson Financial Times
Kate Bingham UK Vaccine Taskforce, SV Health Investors
Professor James Logan The London School of Hygience and Tropical Medicine
Rajeev Venkayya Takeda Pharmaceuticals
Sean Marett BioNTech.jpg)
Peter Stein Norgine Group
Mike Ward Decision Resources Group, part of Clarivate
Elisa Petris Syncona.jpg)
Guillaume Vignon BeiGene
Linden Thomson AXA Investment Managers
Philippe Lopes-Fernandes Ipsen
Kevin Mannix Teva Pharmaceutical Industries Ltd
Stavros Mercouris KKR
Isabella Eichler Altor Private Equity
Kasim Kutay Novo Holdings
Werner Lanthaler Evotec
Anne Marden JP Morgan Asset Management
Jan van de Winkel Genmab
Geraldine O'Keeffe LSP
Antoine Papiernik Sofinnova Partners
Martin Murphy Syncona
Edwin Moses NED Various
Annalisa Jenkins NED Various
Paul Major Bellevue Asset Management
Professor Tony Young OBE NHS England
Roel Bulthuis Inkef Capital
David Pinniger Polar Capital
Vicky Darbyshire JP Morgan Asset Management
Hakan Goker M Ventures
George Freeman Government adviser on Life Sciences
Catherine Pickering iOnctura
Gavin MacGregor HBM Partners
Andrew Holder Mole Valley Asset Management
Richard Girling Centreview Partners
Justin Stebbing Imperial College London
Deborah Harland SR One
Lisa Urquhart Vantage
Thomas Burt Sofinnova
Harry Destecroix Unit DX
Ilan Chaitowitz Nomura Asset Management
Dale Raine Lazard
Jonathan Tobin Arix Bioscience
Soren Moller Novo Holdings
Jasper Bos M Ventures
Marc Booty Pictet Asset Management
Eva Haas Optimum Strategic Communications
Ian Nicholson F2G
Anker Lundemose Mission Therapeutics
Sam Fazeli Bloomberg Intelligence
Professor Sir Michael Rawlins NICE
Andy Richards CBE NED Various
Rice Powell Fresenius Medical Care
Renee Aguiar-Lucander Calliditas Therapeutics
John Dawson Oxford Biomedica
Lisa Anson Redx Pharma
Francesco de Rubertis Medicxi
Amber Tong Endpoints News
Ulrica Slåne Bjerke Arctic Asset Management
Maina Bhaman Sofinnova Partners
Optimum Strategic Communications
Optimum Strategic Communications is an international healthcare communications firm which specialises in strategic investor relations, corporate and financial communications. Our senior team of healthcare specialists, based in London, Amsterdam, Stockholm, Zurich, and New York, are experienced and trusted advisors to some of the world’s most exciting public and private companies, both large and small, across pharmaceuticals, medtech, biotech, health tech and healthcare services.
Over the last 20 years we have worked with over 300 healthcare companies, advising them on financial communications and investor relations, including major corporate activity such as fundraising, IPOs, and M&A, as well as corporate reputation and crisis scenarios.
We have an exceptional network of contacts across the international investment community in Europe and the US; contacts we have built and maintained over the last three decades. Our team includes ex-fund managers and analysts, scientists, as well as financial and corporate communications specialists.
For more information please visit www.optimumcomms.com
Mary Clark, Optimum Strategic Communications
Billions of dollars have been raised by VC funds and invested in the Life Sciences industry in recent years, but can this be sustained with more volatile global markets coupled with high inflation? Join the discussion as our expert panel considers what the future holds.
Chair: Stephen Hansen, BioCentury
Roel Bulthuis, Inkef Capital
Hakan Goker, M Ventures
Karin Kleinman, MRL Ventures Fund (MRLV), corporate venture arm of Merck & Co
Søren Møller, Novo Holdings
Building a successful biotech has never been easy. One of the industry’s most well-known entrepreneurs shares the secrets of his success.
Chair: Mike Ward, Clarivate
Werner Lanthaler, Evotec
With public markets increasingly tricky to navigate, what sources of capital are available to fund growth and what do you need to do to access them? Our panel will share their views on how best to navigate this critical phase of corporate development.
Chair: Hannah Kuchler, Financial Times
Olivia Cavlan, Alchemab Therapeutics
Andrea Ponti, GHO Capital
Gil Bar-Nahum, Jefferies
Tom Burt, Sofinnova Partners
Hindsight can help hone our expectations for the future. Dan & Gareth look into their crystal ball and discuss Biotech innovation – what has got us to where we are, and what is to come.
Chair: Amy Brown, Evaluate Vantage
Dan Mahony, Evotec
Gareth Powell, Polar Capital
We look forward to welcoming you to our virtual conference.
Wellcome Collection, 183 Euston Road, London, NW1